OncoMatch

OncoMatch/Clinical Trials/NCT06609187

A Study of GNC-077 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors

Is NCT06609187 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies GNC-077 for breast cancer.

Phase 1RecruitingSichuan Baili Pharmaceutical Co., Ltd.NCT06609187Data as of May 2026

Treatment: GNC-077This study is an open-label, multicenter, dose-escalation and cohort expansion phase I clinical study to evaluate the safety, tolerability, pharmacokinetics characteristics or preliminary efficacy and antitumor activity in patients with locally advanced or metastatic breast cancer and other solid tumors.

Check if I qualify

Extracted eligibility criteria

Cancer type

Breast Carcinoma

Tumor Agnostic

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Cannot have received: chemotherapy

Exception: not within 4 weeks or 5 half-lives before first dose

Chemotherapy, biological therapy, immunotherapy and other anti-tumor therapies have been used within 4 weeks or 5 half-lives before the first dose

Cannot have received: biological therapy

Exception: not within 4 weeks or 5 half-lives before first dose

Chemotherapy, biological therapy, immunotherapy and other anti-tumor therapies have been used within 4 weeks or 5 half-lives before the first dose

Cannot have received: immunotherapy

Exception: not within 4 weeks or 5 half-lives before first dose

Chemotherapy, biological therapy, immunotherapy and other anti-tumor therapies have been used within 4 weeks or 5 half-lives before the first dose

Cannot have received: mitomycin (mitomycin)

Exception: not within 6 weeks before first dose

Mitomycin and nitrosoureas were administered within 6 weeks before the first dose

Cannot have received: nitrosourea (nitrosoureas)

Exception: not within 6 weeks before first dose

Mitomycin and nitrosoureas were administered within 6 weeks before the first dose

Cannot have received: antimetabolite (fluorouracil)

Exception: oral drugs such as fluorouracil

Oral drugs such as fluorouracil

Lab requirements

Blood counts

bone marrow function should meet the requirements

Kidney function

renal function should meet the requirements

Liver function

liver function should meet the requirements

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify